Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2 Sources of data to characterize the ADPKD clinical phenotype

Published byLiani Sugiarto Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 2 Sources of data to characterize the ADPKD clinical phenotype"— Presentation transcript:

1 Figure 2 Sources of data to characterize the ADPKD clinical phenotype
Figure 2 | Sources of data to characterize the ADPKD clinical phenotype. Beyond vital information obtained from analyses of a patient's medical and family history, molecular genetic and imaging techniques can be used to further characterize the current disease status and prognosis of a patient. Other modalities that can provide clinically relevant information include blood-pressure monitoring and analyses of bodily fluids for the presence of specific biomarkers. LVH, left ventricular hypertrophy. Lanktree, M. B. & Chapman, A. B. (2017) New treatment paradigms for ADPKD: moving towards precision medicine Nat. Rev. Nephrol. doi: /nrneph

Download ppt "Figure 2 Sources of data to characterize the ADPKD clinical phenotype"

Similar presentations

Clinical Section: Added Value of a Paper (Novelty, quality, solidity, timely, etc …) Number of patients (families): ranges from > 1 to N … Natural history.

Clinical Section: Added Value of a Paper (Novelty, quality, solidity, timely, etc …) Number of patients (families): ranges from > 1 to N … Natural history.
Definitions and classification of office blood pressure levels (mmHg) Modified by ESC Guidelines 2013 CARDIOcheckAPP.

Definitions and classification of office blood pressure levels (mmHg) Modified by ESC Guidelines 2013 CARDIOcheckAPP.
Dr Godfrey Grech University of Malta

Dr Godfrey Grech University of Malta
Cancers of the Digestive System November 19, 2007 NCDD Meeting Chair: John M. Carethers, MD Vice Chair: Robert Sandler, MD, MPH.

Cancers of the Digestive System November 19, 2007 NCDD Meeting Chair: John M. Carethers, MD Vice Chair: Robert Sandler, MD, MPH.
European Patients’ Academy on Therapeutic Innovation Challenges in Personalised Medicine.

European Patients’ Academy on Therapeutic Innovation Challenges in Personalised Medicine.
Status Epilepticus Presenting After Traumatic Brain Injury in Infants Kurz, J. E.1; Zelleke, T.1; Carpenter, J.1; Dean, N.2; Singh, J.1; Kadom, N.3; Gaillard,

Status Epilepticus Presenting After Traumatic Brain Injury in Infants Kurz, J. E.1; Zelleke, T.1; Carpenter, J.1; Dean, N.2; Singh, J.1; Kadom, N.3; Gaillard,
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.
Figure 2 The US Centers for Disease Control and

Figure 2 The US Centers for Disease Control and
Figure 4 Time course of the development of physiological changes

Figure 4 Time course of the development of physiological changes
Figure 6 Effects of adiponectin on podocyte function

Figure 6 Effects of adiponectin on podocyte function
Figure 4 The theoretical contribution of genetic and

Figure 4 The theoretical contribution of genetic and
Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.

Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.
Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.

Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.
Figure 3 Angiotensin signalling in adiporenal crosstalk

Figure 3 Angiotensin signalling in adiporenal crosstalk
Figure 4 Interactions between adipose, the microbiome and kidney

Figure 4 Interactions between adipose, the microbiome and kidney
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Figure 1 Mechanisms of kidney injury in the setting of obesity

Figure 1 Mechanisms of kidney injury in the setting of obesity
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Similar presentations

Ads by Google